Biomotion Sciences Ordinary Shares (SLXN) - Total Assets
Based on the latest financial reports, Biomotion Sciences Ordinary Shares (SLXN) holds total assets worth $4.60 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Biomotion Sciences Ordinary Shares to assess how comfortably operating cash covers total debt obligations.
Biomotion Sciences Ordinary Shares - Total Assets Trend (2020–2025)
This chart illustrates how Biomotion Sciences Ordinary Shares's total assets have evolved over time, based on quarterly financial data. See Biomotion Sciences Ordinary Shares shareholders equity for net asset value and shareholders' equity analysis.
Biomotion Sciences Ordinary Shares - Asset Composition Analysis
Current Asset Composition (December 2025)
Biomotion Sciences Ordinary Shares's total assets of $4.60 Million consist of 92.0% current assets and 8.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 83.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Biomotion Sciences Ordinary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Biomotion Sciences Ordinary Shares (SLXN) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biomotion Sciences Ordinary Shares's current assets represent 92.0% of total assets in 2025, an increase from 40.0% in 2020.
- Cash Position: Cash and equivalents constituted 83.0% of total assets in 2025, up from 40.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Biomotion Sciences Ordinary Shares Competitors by Total Assets
Key competitors of Biomotion Sciences Ordinary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
Biomotion Sciences Ordinary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.00 | 3.22 | 7.07 |
| Quick Ratio | 1.00 | 3.22 | 7.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.00K | $5.33 Million | $509.09K |
Biomotion Sciences Ordinary Shares - Advanced Valuation Insights
This section examines the relationship between Biomotion Sciences Ordinary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.41 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | 152.0% |
| Total Assets | $7.21 Million |
| Market Capitalization | $787.71K USD |
Valuation Analysis
Below Book Valuation: The market values Biomotion Sciences Ordinary Shares's assets below their book value (0.11x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Biomotion Sciences Ordinary Shares's assets grew by 152.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Biomotion Sciences Ordinary Shares (2020–2025)
The table below shows the annual total assets of Biomotion Sciences Ordinary Shares from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.21 Million | +152.01% |
| 2024-12-31 | $2.86 Million | -45.53% |
| 2023-12-31 | $5.26 Million | -43.68% |
| 2022-12-31 | $9.33 Million | -91.91% |
| 2021-12-31 | $115.41 Million | +89092.47% |
| 2020-12-31 | $129.40K | -- |
About Biomotion Sciences Ordinary Shares
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for … Read more